How much funding has Dianthus Therapeutics raised?

Dianthus Therapeutics has raised $100.0M in total funding, most recently a Series A round.

Who are Dianthus Therapeutics's investors?

Dianthus Therapeutics's investors include 5AM Ventures, Avidity Partners, Fidelity Management.

When was Dianthus Therapeutics founded?

Dianthus Therapeutics was founded in 2021.

Where is Dianthus Therapeutics headquartered?

Dianthus Therapeutics is headquartered in New York, New York, United States.

What industry is Dianthus Therapeutics in?

Dianthus Therapeutics operates in Biotech, Healthcare.

How many employees does Dianthus Therapeutics have?

Dianthus Therapeutics has 11-50 employees.

Dianthus Therapeutics

IPO

Public · New York, United States · Founded 2021 · $100.0M raised

Biotech

Healthcare

Headquarters: New York, New York
Employees: 11–50
Founded: 2021
Business Model: B2B
Website: dianthustx.com

Total Funding: $100.0M
Last Round: $100.0M Series AApr 2022
Rounds: 1
Type: Public

About

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation complement-targeted antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, claseprubart (DNTH103), is engineered with extended half-life and high selectivity for active C1s complement protein, enabling self-administered subcutaneous injections. A second candidate, DNTH212, is a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation.

Summary

Dianthus Therapeutics is a Biotech company based in New York, United States, founded in 2021. It has raised $100.0M in total across 1 round, most recently a $100.0M Series A round in Apr 2022. Investors include 5AM Ventures, Avidity Partners and Fidelity Management.

LinkedIn X (Twitter)